Reported about 1 month ago
JPMorgan analyst Jessica Fye has reduced Moderna's price target from $40 to $33, citing conservative estimates for RSV and influenza sales. The new forecast anticipates RSV sales for 2025 to be around $148 million, down from a previous estimate of $210 million, reflecting a total revenue projection for FY25 at $2.1 billion, which is slightly below the consensus of $2.2 billion.
Source: YAHOO